Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 01/27/23
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's WhyZacks Investment Research • 01/10/23
Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 12/15/22
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & ExpositionPRNewsWire • 12/11/22
Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High?Zacks Investment Research • 12/06/22
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual CongressPRNewsWire • 12/06/22
Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/11/22
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022PRNewsWire • 11/10/22
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & ExpositionPRNewsWire • 11/03/22
Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual CongressPRNewsWire • 11/03/22
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual MeetingPRNewsWire • 10/05/22
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/07/22
Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering TechSeeking Alpha • 09/04/22
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022PRNewsWire • 08/11/22
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 08/08/22
Poseida Therapeutics: Even After Recent Partnership, Additional Upside PossibleSeeking Alpha • 08/03/22
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic MalignanciesPRNewsWire • 08/03/22
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory BoardPRNewsWire • 07/26/22
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T ProductsPRNewsWire • 06/29/22